Business Context and Reporting Period
ImmunityBio, Inc. (Nasdaq: IBRX) filed a Current Report on Form 8-K dated May 14, 2026, reporting the entry into a material definitive agreement. The filing covers events occurring on May 14, 2026, with a press release issued on May 16, 2026.
Key Financial Metrics
This filing is a Current Report (8-K) and does not contain audited financial statements, revenue, profit, cash flow, or balance sheet data. The filing text does not provide clear values for financial metrics such as margins, debt, or liquidity.
Material Changes and Agreements
On May 14, 2026, ImmunityBio entered into an exclusive development and supply agreement with Japan BCG Laboratory (JBL). Key terms include:
- Product: Tokyo-172 strain of Bacillus Calmette-Guerin (BCG).
- Scope: JBL will manufacture and exclusively supply the product to ImmunityBio for the United States and its territories.
- Responsibilities: ImmunityBio is solely responsible for development, preclinical studies, clinical trials, and regulatory approvals.
- Term: Initial term of 10 years from the date of FDA approval.
- Financial Terms: No payment is due prior to FDA approval. Vials for regulatory submission are provided at no cost. Post-approval, ImmunityBio commits to purchasing at least 2 batches per year.
- Expansion Rights: ImmunityBio holds a right of first negotiation for jurisdictions outside the U.S. (excluding certain Asian regions) after commercial production begins.
Outlook, Risks, and Management Commentary
Management indicated that ImmunityBio will use commercially reasonable efforts to launch and commercialize the product upon FDA approval. The agreement includes standard termination clauses for material breach, insolvency, or for convenience by ImmunityBio. The full text of the agreement is expected to be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2026.
Investor Verification Checklist
- Verify the specific clinical development timeline and regulatory strategy for the Tokyo-172 BCG strain.
- Review the full text of the agreement in the upcoming Form 10-Q for detailed pricing, volume commitments, and termination penalties.
- Assess the financial impact of the "2 batches per year" minimum purchase commitment post-approval.
- Confirm the status of any existing BCG-related assets or competing products in ImmunityBio's pipeline.